Chemoprevention of head and neck cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 10, 2005, Pages 763-765

  Mulshine, James L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CAROTENE; BIOLOGICAL MARKER; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FENRETINIDE; ISOTRETINOIN; RETINOID DERIVATIVE; RETINOL DERIVATIVE;

CANCER MORTALITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HEAD AND NECK CANCER; HUMAN; LEUKOPLAKIA; LUNG CANCER; MOUTH CANCER; NONHUMAN; NOTE; RESPIRATORY TRACT CANCER; RETINOL DEFICIENCY; SIDE EFFECT; SKIN CANCER;

ANTICARCINOGENIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; RETINOIDS;

EID: 28944452521     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Smith W, Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol. 2005;55:143-152.
2. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol. 2005;23:346-356.
3. Rhee JC, Khuri FR, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist. 2004;9:302-311.
4. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled IIb trial of the cyclooxygenase inhibitor keterolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10:1565-1573.
5. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res. 2002;62:519-5125.